TripleWhale vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Columbus ecommerce analytics platform founded 2021; raised $25M+; helps Shopify DTC brands measure paid social attribution after iOS 14 undermined Facebook Pixel tracking accuracy.
About
TripleWhale was founded in 2021 in Columbus, Ohio and raised over $25M to build a data analytics and attribution platform for Shopify-based DTC brands. The company entered the market at the same time that iOS 14 privacy changes were undermining Facebook Pixel attribution, positioning TripleWhale as a solution to the attribution crisis that DTC brands were experiencing as their ability to measure paid social performance deteriorated. The platform grew rapidly through strong word-of-mouth in the DTC community.\n\nTripleWhale's platform consolidates e-commerce, advertising, and operational data from Shopify and connected advertising platforms into a summary dashboard that gives DTC operators a real-time view of their business performance. Its proprietary pixel collects first-party data to power attribution modeling that supplements platform-reported data from Meta and Google. The platform also includes creative analytics that help marketing teams understand which ad creative variants are driving the best performance.\n\nTripleWhale has expanded beyond its original analytics dashboard into a broader suite including a creative analytics tool, a ChatGPT-powered AI assistant called Moby, and a data science layer. The company serves thousands of Shopify DTC brands and competes against Northbeam, Polar Analytics, and Daasity, differentiating through its Shopify ecosystem depth, strong community presence in DTC marketing circles, and its product expansion into AI-powered business intelligence.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.